BioMérieux Stock: Institut Mérieux Strengthens Its Position by €83 Million in Two Sessions
BioMérieux stock edges up 0.14% to €71.15 at midday this Thursday, May 7, in a nearly flat SBF 120 (-0.1%). The stock is attempting to consolidate after a nearly 25% drop over three months. Against this backdrop, Institut Mérieux, the reference shareholder, has just strengthened its position in the capital by more than €83 million in two transactions.
Historic Shareholder's Strategic Acquisitions
The historic shareholder of the Lyon-based group conducted two close acquisitions on the market. On April 30, Institut Mérieux acquired 779,245 shares at a unit price of €69.99, totaling €54.54 million. On May 4, another transaction involved the repurchase of 404,367 shares at €71.96, adding an additional €29.10 million. These purchases came after the stock's decline following the annual target warning issued on April 23, which led to a 17% drop in one session and set a seven-year low at €68.05.
Technical Setup: RSI at 28, Price Recovery from Bollinger Lows
At €71.15, the stock remains far from its moving averages: the MM50 is at €89.10 and the MM200 at €105.74, representing a respective gap of 25% and 49% above the price. An RSI at 28 indicates a persistent oversold zone, following the post-publication drop on April 23. The price is moving in the lower part of the Bollinger bands, near the lower boundary at €61.25, and is attempting stabilization above the technical support identified at €68.25. One-month volatility has returned to 8.18%. Looking ahead, the financial calendar points to the publication of the semi-annual results 2026 on July 28, which will assess the trajectory after the lowering of annual targets announced at the end of April.
